P-ISSN: 2617-9806
E-ISSN: 2617-9814

Impact Factor: RJIF 5.2
www.nursingjournal.net

International Journal of Advance Research in Nursing

Volume 7; Issue 2; Jul-Dec 2024; Page No. 99-102

Received: 11-06-2024
Accepted: 16-07-2024

Indexed Journal
Peer Reviewed Journal

Classical Homocystinuria (HCU): Overview and dietary management

[1]Niranjani S, [2]Preethi R and [3]Mithra R

[1-3] Head of the Department, Community Health Nursing, Tagore College of Nursing, Chennai, Tamil Nadu, India

Corresponding Author: Niranjani S

DOI: https://doi.org/10.33545/nursing.2024.v7.i2.B.406

Abstract

Homocystinuria (HCU) is a rare genetic disorder characterized by a deficiency in the enzyme cystathionine β-synthase (CBS), resulting in impaired metabolism of the amino acid methionine and elevated levels of homocysteine. With an estimated incidence of 1 in 100,000 live births globally, HCU poses significant challenges in clinical management due to its multisystemic manifestations and potential for severe complications if left untreated. The disorder affects individuals of all ethnic backgrounds, presenting a wide spectrum of clinical symptoms, from mild to life-threatening complications. Vascular complications, skeletal abnormalities, ocular manifestations, and neurological deficits underscore the complexity of managing HCU. Cardiovascular complications, including premature atherosclerosis and thromboembolic events, are major contributors to morbidity and mortality. Skeletal manifestations such as osteoporosis and ocular complications like ectopia lentis are common features, while neurological manifestations encompass intellectual disability and psychiatric disturbances. Early diagnosis through biochemical and genetic testing is crucial for prompt intervention to prevent or minimize complications. Current management strategies focus on a multifaceted approach, including dietary restriction of methionine, supplementation with vitamins and betaine, and close monitoring of metabolic parameters. Emerging dietary strategies offer promise for improving outcomes in HCU management. These include exploring the optimal balance between methionine restriction and amino acid supplementation, personalized dietary plans tailored to individual metabolic profiles, targeted nutrient interventions, integration of bioactive compounds and functional foods, leveraging technology for monitoring and support, and fostering collaborative research initiatives. By advancing our understanding of HCU pathophysiology and developing novel treatment modalities, we can strive to improve the quality of life and long-term prognosis for affected individuals.

Keywords: Dietary strategies, homocystinuria, overview and dietary management

Introduction

Classical Homocystinuria (HCU) is a rare, autosomal recessive disorder characterized by a deficiency in the enzyme cystathionine β-synthase (CBS), resulting in impaired metabolism of the amino acid methionine. This metabolic defect leads to elevated levels of homocysteine and its metabolites in the blood and urine, a condition termed hyperhomocysteinemia. First described by Carson and Neill in 1962, HCU represents a significant challenge in clinical management due to its multisystemic manifestations and potential for severe complications if left untreated.

HCU occurs with an estimated incidence of 1 in 100,000 live births globally, making it one of the most common inherited disorders of sulphur metabolism. It affects individuals of all ethnic backgrounds, although certain populations, such as those of Irish descent, have a higher prevalence. The clinical presentation of HCU can vary widely, ranging from mild symptoms in some individuals to severe, life-threatening complications in others.

This disorder primarily affects the cardiovascular, skeletal, ocular, and central nervous systems. Vascular complications, including thromboembolic events and premature atherosclerosis, represent significant morbidity and mortality factors in individuals with untreated HCU. Additionally, skeletal abnormalities such as osteoporosis and ectopia lentis (dislocation of the lens) are common features of the disease. Neurological manifestations, including intellectual disability, psychiatric disturbances, and seizures, further contribute to the complexity of managing HCU. The diagnosis of HCU relies on biochemical testing, including measurement of plasma homocysteine levels and assessment of methionine metabolism. Genetic testing can confirm the diagnosis and identify disease-causing mutations in the CBS gene. Early detection and intervention are essential to prevent or minimize the development of complications associated with HCU. Management of HCU involves a multifaceted approach, including dietary restriction of methionine, supplementation with cofactors such as vitamin B6, B12, folate, and betaine, and close monitoring of metabolic parameters. Compliance with dietary and medical interventions is crucial to achieving optimal outcomes and improving the quality of life for individuals with HCU.

Overview of homocysteine metabolism

Homocysteine metabolism is a crucial biochemical pathway in the body involved in the conversion of homocysteine, a sulphur-containing amino acid, into other compounds.

Here's an overview:

1. **Formation of Homocysteine:** Homocysteine is produced as an intermediate in the metabolism of methionine, an essential amino acid obtained from the diet. Methionine is converted to homocysteine via the removal of a methyl group.
2. **Remethylation Pathway:** Homocysteine can be remethylated back to methionine through two main pathways:

- **Methionine Synthase Pathway:** This pathway requires vitamin B12 (cobalamin) as a cofactor. It involves the transfer of a methyl group from 5-methyltetrahydrofolate (5-MTHF) to homocysteine to form methionine.
- **Betaine Homocysteine Methyl transferase Pathway:** Betaine, derived from dietary sources like choline, donates a methyl group to homocysteine, forming methionine and dimethylglycine.

3. **Transsulfuration Pathway:** Homocysteine can also be metabolized via the transsulfuration pathway, where it is converted to cystathionine by cystathionine beta-synthase (CBS), using vitamin B6 (pyridoxal phosphate) as a cofactor. Cystathionine is then converted to cysteine, which can further be utilized in various physiological processes or be excreted.
4. **Clearance and Excretion:** Any excess homocysteine that is not converted through these pathways can be oxidized or excreted via the kidneys.
5. **Factors Affecting Homocysteine Levels:** Several factors influence homocysteine metabolism and levels in the body, including genetics, dietary intake of vitamins such as B6, B12, and folate, as well as lifestyle factors such as smoking, alcohol consumption, and certain medications.
6. **Health Implications:** Elevated levels of homocysteine (hyperhomocysteinemia) have been associated with an increased risk of cardiovascular disease, stroke, cognitive decline, and other health conditions. Conversely, deficiencies in the vitamins involved in homocysteine metabolism (B6, B12, folate) can also lead to elevated homocysteine levels and related health issues.

Clinical manifestations and complications

Classical homocystinuria, also known as cystathionine beta-synthase (CBS) deficiency, is a rare autosomal recessive disorder characterized by impaired metabolism of the amino acid methionine, leading to elevated levels of homocysteine in the blood and urine. This condition can lead to various clinical manifestations and complications, including:

1. Ocular Manifestations

- Ectopia lentis (dislocation of the lens of the eye), which is the most common ocular complication.
- Myopia (near-sightedness) and other refractive errors.
- Glaucoma (increased pressure within the eye), which can lead to optic nerve damage and vision loss if left untreated.

2. Skeletal Manifestations

- Osteoporosis and osteoporotic fractures due to decreased bone density.
- Marfanoid habitus, characterized by tall stature, long limbs, and joint laxity, resembling features of Marfan syndrome.

3. Cardiovascular Manifestations

- Increased risk of premature atherosclerosis and cardiovascular disease, including coronary artery disease, stroke, and peripheral vascular disease.
- Thromboembolic events such as Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) due to hypercoagulability associated with elevated homocysteine levels.

4. Neurological Manifestations

- Intellectual disability and developmental delay, particularly if the condition is not diagnosed and treated early.
- Seizures, strokes, and other neurological complications due to vascular damage caused by elevated homocysteine levels.

5. Connective Tissue Manifestations

- Joint laxity and hypermobility.
- Skeletal deformities such as scoliosis and pectus excavatum (sunken chest).

6. Psychiatric Manifestations

- Behavioural and psychiatric symptoms, including anxiety, depression, and psychosis, though these are less common compared to other manifestations.

7. Other Manifestations

- Skin changes, such as a malar flush (reddish discoloration of the cheeks), and susceptibility to skin lesions like livedo reticularis (a lace-like pattern of reddish-blue discoloration).
- Increased risk of renal complications, including kidney stones and chronic kidney disease.

Dietary strategies in managing homocystinuria

Dietary management plays a critical role in managing homocystinuria by reducing the intake of methionine, the amino acid that leads to elevated homocysteine levels. Here are some dietary strategies:

1. Low Methionine Diet

- Patients with homocystinuria are typically advised to follow a low methionine diet. This involves restricting foods high in methionine, such as meat, fish, poultry, dairy products, eggs, and certain legumes like soybeans.
- Instead, emphasis is placed on consuming foods low in methionine, such as fruits, vegetables, grains, and some legumes like lentils and kidney beans.

2. Medical Foods

- Medical foods formulated specifically for individuals with homocystinuria are available. These products are designed to be low in methionine while providing essential nutrients.
- Medical formulas may include amino acid-based formulas or protein substitutes that are specially formulated to meet nutritional needs while minimizing

methionine intake.

3. Protein Substitutes

- Protein substitutes with reduced methionine content may be used to provide essential amino acids while limiting methionine intake. These substitutes are often prescribed under the guidance of a healthcare provider or dietitian.

4. Monitoring Nutrient Intake

- It's essential for individuals with homocystinuria to monitor their overall nutrient intake, including protein, vitamins, and minerals. This ensures that nutritional needs are met while adhering to dietary restrictions.
- Regular monitoring of blood levels of methionine, homocysteine, and other relevant biomarkers is also important to assess dietary compliance and overall metabolic control.

5. Supplementation

- Supplementation with vitamin B6 (pyridoxine), folate, and vitamin B12 may be necessary to support alternative pathways of homocysteine metabolism.
- Betaine supplementation can help promote remethylation of homocysteine to methionine, reducing homocysteine levels. Betaine is typically derived from sources like beetroot or synthetic betaine anhydrous.

6. Consultation with Healthcare Providers:

- Individuals with homocystinuria should work closely with a healthcare team, including a metabolic specialist, dietitian, and other relevant healthcare professionals.
- Regular follow-up appointments and monitoring are essential to evaluate dietary adherence, metabolic control, and overall health status.

The general dietary recommendations from the American College of Medical Genetics and Genomics (ACMG) and the National Institutes of Health (NIH) for homocystinuria:

1. **Low Protein Diet:** Since homocystinuria involves the metabolism of certain amino acids, particularly methionine, a low-protein diet is often recommended. This typically involves limiting foods high in methionine such as meat, fish, eggs, and dairy products.
2. **Supplementation:** Vitamin B6 (pyridoxine), vitamin B12 (cobalamin), and folic acid (folate) supplementation are often recommended to help normalize homocysteine levels in the blood. These vitamins can help the body metabolize homocysteine properly.
3. **Betaine Supplementation:** Betaine supplementation may also be recommended as it can help lower homocysteine levels by converting it to methionine.
4. **Monitoring and Adjustment:** Regular monitoring of blood homocysteine levels is important, and dietary adjustments may be necessary based on these levels.
5. **Consultation with a Dietitian:** Working with a registered dietitian who has experience in metabolic disorders can be very helpful in developing a personalized dietary plan that meets the individual's nutritional needs while managing homocystinuria.

Newer and emerging dietary strategies for homocystinuria

1. **Methionine Restriction with Amino Acid Supplements:** Research may explore the optimal balance between methionine restriction and supplementation with other essential amino acids to ensure adequate protein intake while minimizing methionine levels in individuals with homocystinuria.
2. **Individualized Dietary Plans:** With advances in personalized nutrition and metabolic profiling, there might be a move towards more individualized dietary plans tailored to the specific needs and metabolic characteristics of each person with homocystinuria. This approach could involve comprehensive assessments of nutrient requirements, metabolic pathways, and genetic factors to optimize dietary management.
3. **Targeted Nutrient Interventions:** Researchers might be investigating the efficacy of specific nutrients, such as choline, betaine, or certain vitamins and minerals, in modulating homocysteine metabolism and reducing oxidative stress associated with homocystinuria. Targeted interventions could involve supplementation or dietary modification to enhance the efficacy of traditional treatment approaches.
4. **Bioactive Compounds and Functional Foods:** There could be exploration into the potential role of bioactive compounds and functional foods in managing homocystinuria. These could include natural compounds with antioxidant or anti-inflammatory properties, as well as foods fortified with nutrients known to influence homocysteine metabolism.
5. **Integration of Technology:** Advancements in digital health and nutritional technology might lead to the development of innovative tools and applications for monitoring dietary intake, tracking metabolic parameters, and providing real-time feedback and support to individuals with homocystinuria. Integration of technology could enhance adherence to dietary recommendations and improve overall management outcomes.
6. **Collaborative Research Initiatives:** Collaboration between researchers, clinicians, patient advocacy groups, and industry partners may foster interdisciplinary research initiatives aimed at exploring novel dietary strategies, conducting clinical trials, and translating research findings into clinical practice.

Conclusion and Recommendations

Homocystinuria is a rare genetic disorder characterized by impaired metabolism of the amino acid methionine, leading to elevated levels of homocysteine in the blood. Without proper management, homocystinuria can result in a range of complications affecting multiple organ systems, including the eyes, skeleton, cardiovascular system, and central nervous system. The current standard of care for homocystinuria involves a combination of dietary restrictions, supplementation with vitamins and betaine, regular monitoring of homocysteine levels, and management of associated complications. However, several challenges remain, including ensuring adherence to dietary therapy, optimizing pharmacological treatments, managing

complications, and addressing psychosocial aspects of the condition.

To improve outcomes for individuals with homocystinuria, the following recommendations are proposed:

1. **Early Diagnosis and Treatment:** Early diagnosis and initiation of treatment are essential for preventing or minimizing the development of complications associated with homocystinuria. Newborn screening programs can help identify affected individuals before symptoms manifest, enabling early intervention.
2. **Multidisciplinary Care:** Homocystinuria management requires a multidisciplinary approach involving metabolic specialists, dietitians, genetic counselors, ophthalmologists, cardiologists, and other relevant healthcare professionals. Collaboration among these specialists is crucial for comprehensive care and optimal outcomes.
3. **Patient Education and Support:** Providing education and support to patients and their families is essential for promoting treatment adherence, self-management, and psychosocial well-being. Patient support groups, educational materials, and access to resources can empower individuals with homocystinuria to effectively manage their condition.
4. **Research and Innovation:** Continued research into the pathophysiology of homocystinuria, as well as the development of novel treatment modalities, such as gene therapy and precision medicine approaches, is needed to advance the field and improve treatment options for affected individuals.

Conflict of Interest: NIL

References

1. Mudd SH, Skovby F, Levy HL, Pettigrew KD. Disorders of transsulfuration. In: The Metabolic Basis of Inherited Disease. 6th Ed. McGraw-Hill; c1985. p. 693-734.
2. Refsum H, Fredriksen Å, Meyer K, Ueland PM, Kase BF. Birth prevalence of homocystinuria. Journal of Pediatrics. 2004;144(6):830-832.
3. Mudd SH, Levy HL, Skovby F. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and Molecular Bases of Inherited Disease. 8th Ed. Vol. 2. McGraw-Hill; c2001, p. 2007-2056.
4. Huemer M, Diodato D, Schwahn B, Schiff M, Bandeira A, Benoist JF, et al. Guidelines for diagnosis and management of the cobalamin-related remethylation disorders cblC, cblD, cblE, cblF, cblG, cblJ and MTHFR deficiency. Journal of Inherited Metabolic Disease. 2019;42(1):5-46.
5. Mudd SH. Hypermethioninemia's of genetic and non-genetic origin: A review. American Journal of Medical Genetics Part C: Seminars in Medical Genetics. 2011;157C(1):3-32.
6. Yap S. Classical homocystinuria: vascular risk and its prevention. Journal of Inherited Metabolic Disease. 2003;26(3):259-265.
7. Gaustadnes M, Ingerslev J, Rüdiger N. Frequency of the 833T>C cystathionine β-synthase gene variant in newborns in Denmark. Journal of Inherited Metabolic Disease. 1999;22(8):854-858.
8. Holmes Morton D, Levy HL, Wilcken BA, editors. Nutrition Management of Inherited Metabolic Diseases: Lessons from Metabolic University. Oxford University Press; c2015.
9. Sacharow SJ, Picker JD, Levy HL, Adam MP. Pagon RA, Adam MP, et al edITOrs. Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency. GeneReviews® [Internet]. University of Washington, Seattle; c2014.

How to Cite This Article
Niranjani S, Preethi R, Mithra R. Classical homocystinuria (HCU): Overview and dietary management. International Journal of Advance Research in Nursing. 2024;7(2):99-102